Daley breast center opens its doors

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Opening of the Maggie Daley Center for Women’s Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.


From left, Mayor Richard Daley, his wife Maggie Daley (seated), Ann Lurie, and Dr. Steven Rosen at the opening of the Maggie Daley Center for Women's Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

CHICAGO-From left, Mayor Richard Daley, his wife Maggie Daley (seated), Ann Lurie, and Dr. Steven Rosen at the opening of the Maggie Daley Center for Women's Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The new center will offer women with breast cancer a centralized location for access to clinical trials and novel therapies, psychosocial services, rehabilitation, and integrative oncology services. The center is a partnership between Northwestern Medical Faculty Foundation, the university's Feinberg School of Medicine, Northwestern Memorial, and the Rehabilitation Institute of Chicago.

Articles in this issue
Who's News
A health insurer actually poses the big question
State breast cancer screening programs struggle financially
Palliative Rx for prostate ca wins OK from FDA
Whole-body MRI finds breast cancer metastases earlier
Brain cancer cells dodge conventional Rx
Eli Lilly joins SNM imaging network
Chemo Added to Surgery Ups OS in Gastric Cancer
Daley breast center opens its doors
Blood count test may predict prognosis in leukemia
Taxane analog shows ‘unequivocal benefit’ in prostate mets
Gemcitabine Sensitizes Invasive Bladder Tumors to Radiation
Researchers identify regulatory protein domains that contribute to tumor cell survival and cancer progression
International cancer diagnosis, treatment varies widely
Multigene assays influence treatment decisions in low-risk breast cancer patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article
3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article